Business
Contract awards
Contract awards.
About this update from Physiomics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8848P\n Physiomics PLC\n 22 October 2021\n \n \n \n \n 22 October 2021\n \n \n \n \n \n Physiomics plc \n \n \n (\"Physiomics\") or (\"the Company\")\n \n \n \n \n \n Contract awards\n \n \n \n \n \n Physiomics plc (AIM: PYC), \n the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, \n is pleased to announce that it has been awarded two further contracts by existing client Merck KGaA (\"Merck\") that it expects to be completed by the end of this calendar year. These projects involve simulations of clinical efficacy of drug products in Merck's DNA damage/ repair portfolio.\n \n \n \n \n \n Physiomics CEO, Dr Jim Millen, commented: \"Merck remains a key, valued client and we are pleased to be continuing to work with them on a number of important development programs.\" \n \n \n \n \n \n Enquiries:\n \n \n Physiomics plc \n \n \n Dr Jim Millen, CEO \n \n \n +44 (0)1865 784 980\n \n \n \n \n \n Hybridan LLP (broker)\n \n \n Claire Louise Noyce\n \n \n +44 (0) 203 764 2341\n \n \n \n \n \n Strand Hanson Ltd (NOMAD)\n \n \n James Dance & James Bellman\n \n +44 (0)20 7409 3494\n \n \n Notes to Editor\n \n \n About Physiomics\n \n \n \n \n \n Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.\n \n \n \n \n \n \n This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.Reach is a non-regulatory news service. By using this service ...